卡介菌多糖核酸联合他扎罗汀等治疗寻常性银屑病疗效观察被引量：6

Observation of Curative Effect on Treating Psoriasis Vulgaris by BCG-PSN

下载PDF

导出

摘要目的观察卡介菌多糖核酸联合外用他扎罗汀及糠酸莫米松治疗寻常性银屑病临床疗效。方法患者随机分为两组。治疗组120例采用卡介菌多糖核酸2mL肌注,隔日1次,18次为1疗程;2mL肌注隔2日1次,18次为第2疗程;同时予他扎罗汀凝胶每晚外涂,糠酸莫米松乳膏隔日早晨外涂。对照A组80例仅肌注卡介菌多糖核酸,用法同治疗组;对照B组98例仅外涂他扎罗汀凝胶及糠酸莫米松乳膏,用法同治疗组。结果治疗组有效率91.66%,对照A,B组分别为86.25%,64.78%。治疗组与对照组比较差异有显著性(P1=0.0034,P2<0.0001)。结论卡介菌多糖核酸联合他扎罗汀凝胶及糠酸莫米松乳膏治疗寻常性银屑病疗效确切。 Objective To observe clinical efficacy useing the BCG-PSN combined with external tazarotene and mometasone furoate treating psoriasis vulgaris. Methods The 120 cases in treatment group, BCG-PSN 2mL intramuscular injection,q, o. d , 36 days for first period of treatment, and q. 3. d, another 36 days as the second period, at the same time, endermic medication of tazarotene plastic every night,and mometasone furoate cream in the morning the next day. 80 cases is control group A, medicated with intramuscular injection of BCG-PSN only. 98 cases in the control group B treated with tazarotene geland mometasone furoate cream only. Results The effective rate in the treatment group was 91.66% ; control group A was 86.25% ; control group B was 64.78% . There was a significant difference of effective rate in the treatment group and control group （P1 = 0. 0034 ;P2 〈 0. 0001 ）. Conclusion Jointing BCG-PSN with tazarotene gel and mometasone furoate cream in the treatment of psoriasis vulgaris had a exact effect.

作者姚红娜蒙秉新

机构地区海南省人民医院皮肤科

出处《中国皮肤性病学杂志》 CAS 北大核心 2009年第7期456-457,共2页 The Chinese Journal of Dermatovenereology

关键词卡介菌多糖核酸他扎罗汀糠酸莫米松银屑病 BCG-PSN Tazarotene Mometasone furoate Psoriasis

分类号 R758.63 [医药卫生—皮肤病学与性病学]

引文网络
相关文献

参考文献3

1SZEGEDI A,ALEKSZA M,GONDA A,et al.Elevated rate T helped (Thl) lymphocytes and senm IFN-gamma levels in psoriasis patients[J].Immunol LETT,2003,86:277-280.
2UVIMURA K,YAMAMURA M,FIVENSON DF,et al.The cytokine network in lesional and lesion-free psoriatic skin is charactetized by a T-helper type1 cell-mediated response[J].J Invest Dermatol,1993,101:701.
3张江安,谭升顺,张秉正.他扎罗汀(乙炔维甲酸)的研究进展[J].中国皮肤性病学杂志,2001,15(3):200-202. 被引量：23

二级参考文献19

1[1]Disepio D,Malhotra M,Chandraratna RA,et al.Retinoic acid receptor-nuclear factorinterleukin 6 antagonism.A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker[J].J Bioel Chem,1997,272:2555
2[2]Duvic M,Nagpal S,Asano AT,ct al.Molecular mechanisms of tazarotene action in psoriasis[J].J Am Acad Dermatol,1997,37:s18～s24
3[3]Kashihara-Sawami M,Norris AD.The state of differentiation of cultured human keratinocytes determines the level of intercellular adhesion molecule1(ICAM-1) Expression induced by γ interferon[J].J Invest Dermatol,1992,98:741～747
4[4]Nagpal S,Patel S,Asano AT,et al.Tazarotene-incluced genel(TIG1),a novel retinoic acid receptor-responsive gene in skin[J].J Invest Dermatol,1996,106:269～274
5[5]Nagpal S,Patel S,Jacobe H,et al.Tazarotene-induced gene2(TIG2),a novel retinoid-responsive gene in skin[J].J Invest Dermatol,1997,109:91～95
6[6]Disepio D,Ghosn C,Eckert RL,et al.Identification and characterization of a retinoidinduced class Ⅱ tumor suppressor/growth regulatory gene[J].Proc Natl Acad Sci USA,1998,95:14811～14815
7[7]Virtanen M,Torma H,Vahlquist A.Keratin 4 upregulation by retinoic acid in vivo:A sensitive marker for retinoid bioactivity in human epidermis[J].J Invest Dermatol,2000,114:487～493
8[8]Tang-Liu DD,Matsumoto RM,Usansky JI.Clinical Pharmacokinetics and drug metabolism of tazarotene:a novel topical treatment for acne and psoriasis[J].Clin Pharmacokinet,1999,37:273～287
9[9]Marks R.Pharmacokinetics and safety review of tazarotene[J].J Am Acad Dermatol,1998,39:S134～138
10[10]Shalita AR,Chalker DK,Griffith RF,et al.Tazarotene gel is safe and effective in the treatment of acne vulgaris:a multicenter,double-blind,vehicle-controlled study [J].Cutis,1999,63:349～354